Human medicines European public assessment report (EPAR): DuoTrav, travoprost,timolol, Date of authorisation: 23/04/2006, Revision: 19, Status: Authorised
Decision of the Management Board amending budget No. 04, amending appropriations in budget 2024
Training module EV-M8 - Considerations on the international transfer of personal (health) data in ICSRs -SUSARs originating in the EU
Dear EFIM Colleagues,
The Multimorbidity Working Group is developing Clinical Practice Guidelines for sarcopenia, focusing on the most relevant and pragmatic approaches for patients with multimorbidity.
To select the PICO questions, we highly value the invaluable input of clinicians who manage this issue daily.
We invite you to participate in a short 9-question survey designed to capture your insights and guide us in addressing key challenges in diagnosing and treating sarcopenia in in-patient clinical practice.
Member states contact points for review of national versions of the content of mobile scanning and other technologies
Contact details of national competent authorities for requests to use a sticker to place the Unique Identifier on the outer/immediate packaging of centrally approved products
Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages
Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 June 2024, 09:00 (CEST) to 14 June 2024, 16:30 (CEST)
Rafoxanide (bovine and ovine milk): European Public MRL Assessment Report (EPMAR) - CVMP
PSUSA/00000703/202403